ArticleBMC microbiology2025
Indole compounds produced by gut microbiota after metabolizing tryptophan improve dysmotility in sepsis via the AHR-TRPA1 axis in enteric nerves.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strengths and limitations ofGut microbes reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSepsis represents a major global health challenge, and the resulting impaired intestinal motility can lead to numerous adverse outcomes. Indole compounds produced by gut microbiota after metabolizing tryptophan may improve sepsis-induced intestinal dysmotility, though the underlying mechanism remains unclear. Here, we explored the role of 6-formylindolo[3,2-b]carbazole (FICZ), a gut-derived metabolite of tryptophan, in improving dysmotility in sepsis. We found that FICZ-activated aryl hydrocarbon receptor (AHR) on the Enteric Nervous System (ENS) may represent a future therapeutic target for treating dysmotility in sepsis.
methodsFive days post-fertilization (5dpf) zebrafish underwent intraperitoneal microinjection of Escherichia coli to induce sepsis. Subsequently, zebrafish were treated with varying concentrations of FICZ and Tol-huc-AHR1a overexpression plasmids. Primary methodologies included micro-filming for intestinal motility observation, immunofluorescence for detecting intestinal motility function-related indicators, and PCR for gene-level analysis. Key endpoints included intestinal peristalsis frequency, neutrophil infiltration, smooth muscle contractility, NO levels, and expression levels of AHR1a, AHR2, TRPA1b, and relevant inflammatory genes.
resultsIn septic zebrafish, FICZ reduced intestinal neutrophil infiltration, restored intestinal smooth muscle strength, increased intestinal peristalsis frequency, and enhanced the expression of intestinal AHR1a, AHR2, and transient receptor potential ankyrin 1b(TRPA1b) genes. Overexpression of the AHR1a gene in septic zebrafish reduced the production of the inhibitory neurotransmitter NO by restoring TRPA1b expression in the intestine, thereby restoring intestinal motility. It also restored the low expression level of inflammatory genes in immunocompromised septic zebrafish.
conclusionThe gut microbial metabolite indole improved sepsis-induced intestinal dysmotility via the AHR-TRPA1 axis. AHR may be a future therapeutic target for treating the immunosuppressive state associated with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.